AstraZeneca License With Regeneron For VelocImmune Could Spark Industry Trend
This article was originally published in The Pink Sheet Daily
Executive Summary
Regeneron is seeking to sign multiple deals offering access to the next-generation human monoclonal antibody discovery technology, exec tells "The Pink Sheet" DAILY.
You may also be interested in...
Astellas Signs License For Regeneron’s VelocImmune To Bolster Antibody Platform
Deal, valued at potentially $120 million, is Regeneron’s second for the human monoclonal antibody discovery technology.
Astellas Signs License For Regeneron’s VelocImmune To Bolster Antibody Platform
Deal, valued at potentially $120 million, is Regeneron’s second for the human monoclonal antibody discovery technology.
Astellas Signs License For Regeneron's VelocImmune To Bolster Antibody Platform
Astellas will license Regeneron's human monoclonal antibody discovery technology VelocImmune as part of a strategy to build a new technology platform for the development of antibody drugs, the company said March 30